May 27, 2026

He Raised $70M to Cure Every Disease With AI

Samuel Rodriques, founder of Edison Scientific, shares his journey from physics to building an AI scientist named Kosmos. He discusses how AI agents are already making novel discoveries, including a potential cure for blindness, and are poised to revolutionize drug discovery. The conversation dives into AI's strengths in high-throughput reasoning, the critical bottlenecks in clinical trials, proposed reforms for the US medical system, and whether human scientists will still be needed in an age of hyper-intelligent AI.

Jan 29, 2026

Scaling Cryopreservation with Until Co-Founder and CEO Laura Deming

Laura Deming, co-founder and CEO of Until, discusses the ambitious goal of making reversible cryopreservation a reality. She outlines the company's vision, starting with preserving human organs to revolutionize transplantation and progressing towards whole-body medical hibernation, allowing patients to "pause" biological time and await future cures. The conversation delves into the core scientific challenges, reframing cryopreservation as an engineering problem of heat transfer and managing ice formation, and explores why this promising field has been historically underfunded.

Nov 14, 2025

The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation

Venture capitalists Elliot Hershberg and Lada Nuzhna analyze the structural crises facing the biotech industry, from Eroom's Law driving drug development costs to $2.5 billion, to China's rapid, low-cost clinical trials outmaneuvering US startups. They argue that for American biotech to survive, it must shift from competing on commoditized platforms to inventing entirely new modalities and medicines that are impossible to create without bleeding-edge tools like AI, targeting massive opportunities like aging.